BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35946133)

  • 1. Effect of social disparities on 10 year survival in pediatric patients with Wilms' tumor.
    Chalfant V; Riveros C; Stec AA
    Cancer Med; 2023 Feb; 12(3):3452-3459. PubMed ID: 35946133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Surveillance, Epidemiology and End Results (SEER) program comparison of adult and pediatric Wilms' tumor.
    Ali AN; Diaz R; Shu HK; Paulino AC; Esiashvili N
    Cancer; 2012 May; 118(9):2541-51. PubMed ID: 21918969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Social Disparities on 5-Year Survival Rates in Pediatric Hematologic Malignancies.
    Chalfant V; Riveros C; Bechtel A; Bradfield SM; Stec AA
    J Pediatr Hematol Oncol; 2024 Jan; 46(1):33-38. PubMed ID: 37910818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors affecting lymph node sampling patterns and the impact on survival of lymph node density in patients with Wilms tumor: a Surveillance, Epidemiology, and End Result (SEER) database review.
    Walker JP; Johnson JS; Eguchi MM; Saltzman AF; Cockburn M; Cost NG
    J Pediatr Urol; 2020 Feb; 16(1):81-88. PubMed ID: 31791906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metachronous bilateral Wilms' tumor: the importance of time interval to the development of a second tumor.
    Paulino AC; Thakkar B; Henderson WG
    Cancer; 1998 Jan; 82(2):415-20. PubMed ID: 9445201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of blastemal predominant histology in initially resected Wilms' tumors: a report from the Study Group for Pediatric Solid Tumors in the Kyushu Area, Japan.
    Kinoshita Y; Suminoe A; Inada H; Yagi M; Yanai F; Zaizen Y; Nishi M; Inomata Y; Kawakami K; Matsufuji H; Suenobu S; Handa N; Kohashi K; Oda Y; Hara T; Taguchi T
    J Pediatr Surg; 2012 Dec; 47(12):2205-9. PubMed ID: 23217877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology, clinical features and treatment outcome of Wilms' tumor in Taiwan: a report from Taiwan Pediatric Oncology Group.
    Hung IJ; Chang WH; Yang CP; Jaing TH; Liang DC; Lin KH; Lin DT; Hsiao CC; Hsieh YL; Chen JS; Chang TT; Peng CT; Shu SG; Lin MT; Chen BW; Lin KS;
    J Formos Med Assoc; 2004 Feb; 103(2):104-11. PubMed ID: 15083240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wilms' tumor at the Children's Hospital of Eastern Ontario: 1990-2001.
    Pianezza ML; Rubin S; Bass J; Chou S; Pike JG; Leonard MP
    Can J Urol; 2004 Feb; 11(1):2151-6. PubMed ID: 15003157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic histology Wilms' tumors registered to the Japan Wilms' Tumor Study Group are less aggressive than that in the National Wilms' Tumor Study 5.
    Oue T; Koshinaga T; Takimoto T; Okita H; Tanaka Y; Nozaki M; Haruta M; Kaneko Y; Fukuzawa M;
    Pediatr Surg Int; 2016 Sep; 32(9):851-5. PubMed ID: 27473009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wilms' tumor: past, present and (possibly) future.
    Spreafico F; Bellani FF
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):249-58. PubMed ID: 16445377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms' tumors: a report from the National Wilms' Tumor Study.
    Green DM; Breslow NE; Beckwith JB; Takashima J; Kelalis P; D'Angio GJ
    J Clin Oncol; 1993 Jan; 11(1):91-5. PubMed ID: 8380295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of lymph node sampling and the impact of lymph node density in favorable histology Wilms tumor: An analysis of the national cancer database.
    Saltzman AF; Carrasco A; Amini A; Aldrink JH; Dasgupta R; Gow KW; Glick RD; Ehrlich PF; Cost NG
    J Pediatr Urol; 2018 Apr; 14(2):161.e1-161.e8. PubMed ID: 29133167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
    Dome JS; Cotton CA; Perlman EJ; Breslow NE; Kalapurakal JA; Ritchey ML; Grundy PE; Malogolowkin M; Beckwith JB; Shamberger RC; Haase GM; Coppes MJ; Coccia P; Kletzel M; Weetman RM; Donaldson M; Macklis RM; Green DM
    J Clin Oncol; 2006 May; 24(15):2352-8. PubMed ID: 16710034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between different levels of lipid metabolism‑related enzymes and fatty acid synthase in Wilms' tumor.
    Wang X; Du G; Wu Y; Zhang Y; Guo F; Liu W; Wu R
    Int J Oncol; 2020 Feb; 56(2):568-580. PubMed ID: 31894270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.
    Green DM; Breslow NE; Beckwith JB; Finklestein JZ; Grundy PE; Thomas PR; Kim T; Shochat SJ; Haase GM; Ritchey ML; Kelalis PP; D'Angio GJ
    J Clin Oncol; 1998 Jan; 16(1):237-45. PubMed ID: 9440748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localized Wilms' tumor in low-middle-income countries (LMIC): how can we get better?
    Asfour HY; Khalil SA; Zakaria AS; Ashraf ES; Zekri W
    J Egypt Natl Canc Inst; 2020 Aug; 32(1):32. PubMed ID: 32794016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monochemotherapy: a study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group.
    Pritchard-Jones K; Kelsey A; Vujanic G; Imeson J; Hutton C; Mitchell C; ;
    J Clin Oncol; 2003 Sep; 21(17):3269-75. PubMed ID: 12947062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy in Wilms' tumour.
    Thomas PR
    Ann Acad Med Singap; 1996 May; 25(3):425-8. PubMed ID: 8876911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
    Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
    Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor.
    Ortiz MV; Ahmed S; Burns M; Henssen AG; Hollmann TJ; MacArthur I; Gunasekera S; Gaewsky L; Bradwin G; Ryan J; Letai A; He Y; Naranjo A; Chi YY; LaQuaglia M; Heaton T; Cifani P; Dome JS; Gadd S; Perlman E; Mullen E; Steen H; Kentsis A
    JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.